Abstract 30P
Background
Accelerated partial breast irradiation (APBI) is now widely adopted in the treatment with low risk early breast cancer worldwide. Both stereotactic body radiotherapy (SBRT) using Cyberknife (CK) and interstitial brachytherapy (IB) are available for APBI. This study was designed to compare the dosimetric characteristics of organ at risk and the clinical outcome between two different techniques.
Methods
Forty-four patients with left sided early breast cancer treated by APBI in our institute were reviewed. The radiation doses are 30Gy in 5 fractions, in 5 consecutive days using CK and 34Gy in 10 fractions, BID in 5 consecutive days using IB. Dosimetric parameters of OARs were calculated for both techniques and compared. The preliminary clinical outcomes include the local recurrence rate, acute toxicity (CTCAE V5.0) and cosmetic evaluation (Harvard scales) were analyzed.
Results
The median follow up time of CK group and IB group were 19.3 months (range: 4.5∼48.4 months) and 53.5months, respectively. Two patients from IB group had sentinel lymph node micrometastasis in the final pathology report and whole breast irradiation plus regional lymph node irradiation was added subsequently. One patient from IB group had regional lymph node recurrence during follow up and underwent surgery and re-irradiation with stable disease now. Most common acute toxicity was grade 1 radiation dermatitis. Neither radiation pneumonitis nor heart events were noted during the follow up. Multiple small scars left for more than 6 months in a few patients after interstitial brachytherapy. Patients reported cosmetic results according to Harvard scales, with “good” score in most patient of IB group and no cases described as “poor”. Dosimetric parameters of OAR showed the heartV150cGy of CK and IB was 23.5% and 59.2%. The mean heart dose of CK and IB were 117.1cGy and 215.6cGy.
Conclusions
APBI by SBRT using CK is a non-invasive procedure and has better dose-sparing effect on the heart. There were less risks of wound infection or delayed wound healing when using CK. Since no small scars left on the breast when using CK, better cosmetic outcome is expected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract